This application proposes to establish a Medication Development Unit (MDU) in Los Angeles, dedicated to rapidly evaluating potential pharmacotherapeutic agents for the treatment of cocaine and methamphetamine abuse and dependence. The proposed MDU, comprising two clinical trial components, and a core, replaces the existing P50 Medication Development Center and will sharpen the research focus on stimulants. The Core will provide central support and be responsible for personnel management, budget, purchasing and contracts, central laboratory, recruitment, quality assurance, training, data management and statistical support, dissemination of research results, and coordination of local, national and international training activities and scientific presentations. The Core is itself embedded within the greater Los Angeles Addiction Research Consortium, facilitating resource sharing and reducing the overall cost. Both clinical trial components will take advantage of refinement of the current rapid cocaine medications evaluation strategy to screen medications suitable for further development. The methamphetamine component will, in addition, address neurocognitive dysfunctions specific to chronic methamphetamine abuse. All studies will utilize central recruitment; uniform operating procedures; standardized CRFs to the extent possible; common outcome measure, data collection procedures, quality assurance, data analysis and interpretation, and dissemination of study results. Each study will recruit 120 subjects randomized to three groups (35 to each active medication arm and 50 to placebo). Each component will evaluate four medications (or combinations) during the period of the grant. These medications will be selected with input from the Medications Development Division's (MDD) Compound Identification Committee. These studies will use the psychosocial treatment platform utilized extensively in our clinical trials. Completion of this work will contribute toward the development of medications for stimulant dependence and toward reduction in HIV risk behaviors. Medications showing promise will be presented to NIDA as candidates for further development through larger samples or multi-site studies. The MDU will also contribute toward establishing, national, and international resource for training, research, and dissemination of research results.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA012755-04
Application #
6523063
Study Section
Special Emphasis Panel (ZDA1-KXA-N (27))
Program Officer
Montoya, Ivan
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
4
Fiscal Year
2002
Total Cost
$1,205,746
Indirect Cost
Name
Friends Research Institute, Inc.
Department
Type
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Brensilver, Matthew; Heinzerling, Keith G; Shoptaw, Steven (2013) Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev 32:449-60
Raisch, Dennis W; Campbell, Heather M; Garnand, David A et al. (2012) Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Qual Life Res 21:1177-83
Miotto, Karen; Hillhouse, Maureen; Donovick, Roger et al. (2012) Comparison of buprenorphine treatment for opioid dependence in 3 settings. J Addict Med 6:68-76
Yang, Xiaowei; Nie, Kun (2008) Hypothesis testing in functional linear regression models with Neyman's truncation and wavelet thresholding for longitudinal data. Stat Med 27:845-63
De La Garza 2nd, R; Mahoney 3rd, J J; Culbertson, C et al. (2008) The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav 89:200-8
Shoptaw, Steve; Heinzerling, Keith G; Rotheram-Fuller, Erin et al. (2008) Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis 27:13-23
Roll, John M; Shoptaw, Steve (2006) Contingency management: schedule effects. Psychiatry Res 144:91-3
Rawson, Richard A; McCann, Michael J; Flammino, Frank et al. (2006) A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 101:267-74
Peck, James A; Reback, Cathy J; Yang, Xiaowei et al. (2005) Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 82:i100-8
Shoptaw, Steven; Reback, Cathy J; Peck, James A et al. (2005) Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend 78:125-34

Showing the most recent 10 out of 21 publications